Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 5Venous Thromboembolism 3Venous Thrombosis 2Lung Neoplasms 2Thromboembolism 1Pulmonary Embolism 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Liver Diseases 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Irinotecan 6Gemcitabine 5130-nm albumin-bound paclitaxel 5Oxaliplatin 4Fluorouracil 4Capecitabine 4Bevacizumab 4Albumin-Bound Paclitaxel 4napabucasin 3Ocoxin 3Leucovorin 3pembrolizumab 2Sorafenib 2Paclitaxel 2Nivolumab 2Drug Therapy 2Cyclophosphamide 2Colonoscopy 2Cetuximab 2Bupivacaine 2Aspirin 2Ascorbic Acid 2trifluridine tipiracil drug combination 1trametinib 1pralsetinib 1penpulimab 1ozanimod 1lutetium Lu 177 dotatate 1linifanib 1hetrombopag 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Digestive System Diseases × Nadroparin × Clear all
NCT00827554 2016-04-01

The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma

Eastern Hepatobiliary Surgery Hospital

Phase 2/3 Completed
100 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡